Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I4V-MC-JAHN long-term baricitinib safety and efficacy in adult atopic dermatitis
2017-000873-35Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients with a response of IGA 0 or 1. Started Sep 2017; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-000873-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000873-35.